MedTrace Logo

First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory

NCT07177508 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2355

Last updated 2025-09-19

No results posted yet for this study

Summary

The goal of this observational study is to explore the impact of a new prevention medicine (nirsevimab) on the burden of Respiratory Syncytial Virus (RSV) disease in children under 2 years of age. The main question it aims to answer is:

How has the incidence of RSV, and Emergency Department presentations and hospital admissions for RSV-related disease changed since nirsevimab was introduced? Participants won't need to do anything extra for this research study, as only routinely collected data will be used for analysis.

Conditions

  • Respiratory Syncytial Viral (RSV) Infection
  • Respiratory Syncytial Virus Hospitalizations
  • Respiratory Syncytial Virus Prevention

Sponsors & Collaborators

  • Nicola Irwin

    lead OTHER

Eligibility

Max Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2025-07-30
Completion
2025-07-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07177508 on ClinicalTrials.gov